Finepoint Capital’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Finepoint Capital’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-563,345	Closed	-$12.3M	–	28
2023 Q3	$12.3M	Buy	563,345 +70,800	+14%	+$1.77M	6.12%	9
2023 Q2	$15.7M	Sell	492,545 -46,900	-9%	-$1.44M	5.42%	9
2023 Q1	$13.2M	Buy	539,445 +22,158	+4%	+$650K	5.03%	16
2022 Q4	$16.3M	Sell	517,287 -19,614	-4%	-$553K	5.27%	12
2022 Q3	$15.2M	Buy	+536,901	New	+$16M	4.99%	14

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Finepoint Capital's CERE Position: Q4 2023 in Review

Finepoint Capital sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q4 2023, closing a stake of 563,345 shares — an estimated $12.3M sold.

Finepoint Capital first reported a position in CERE in Q3 2022 and held it in 5 quarters. The position peaked at $16.3M in Q4 2022. 195 funds tracked by Wall St. Rank hold CERE as of Q4 2023.

Finepoint Capital reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Finepoint Capital sold 563,345 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q4 2023, an estimated $12.3M.
Finepoint Capital first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2022 and held it in 5 quarters.
Finepoint Capital's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $16.3M in Q4 2022.
195 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q4 2023.

Based on Finepoint Capital's 13F filing for Q4 2023, filed 13 Feb 2024.